A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
01/1993
01/12/1993	US5179078 Method of suppressing tumor formation in vivo
01/12/1993	US5179023 Genetic engineering
01/07/1993	WO1993000052A1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
01/07/1993	WO1993000051A1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
01/07/1993	EP0506830A4 Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
01/07/1993	DE4122402A1 Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit Use of interleukin 10 for the manufacture of medicaments having tumor-inhibiting efficacy
01/07/1993	CA2112376A1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
01/07/1993	CA2112375A1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
01/05/1993	US5176996 Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
12/1992
12/30/1992	EP0520029A1 Methods and compositions for the treatment of malignancies in which a protein kinase is associated.
12/29/1992	WO1993001286A2 Localized oligonucleotide therapy
12/29/1992	US5175085 Methods and compositions for diagnosing autoimmune insulin dependent diabetes mellitus
12/29/1992	CA2082411A1 Localized oligonucleotide therapy
12/23/1992	WO1992022651A1 Antisense oligonucleotide inhibition of the ras gene
12/23/1992	WO1992022635A1 Targeted delivery of genes encoding secretory proteins
12/23/1992	WO1992022323A1 Intercellular adhesion molecule-3 and its binding ligands
12/23/1992	WO1992022303A1 Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
12/23/1992	EP0519463A1 Synthetic, catalytic oligonucleotides
12/23/1992	CA2111472A1 Antisense oligonucleotide inhibition of the ras gene
12/23/1992	CA2110387A1 Intercellular adhesion molecule-3 and its binding ligands
12/23/1992	CA2103377A1 Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
12/16/1992	EP0518583A1 Nucleotide sequences
12/16/1992	EP0517909A1 Modified hepatocytes and uses therefor
12/16/1992	EP0517859A1 Oligonucleotide therapies for modulating the effects of herpesviruses
12/16/1992	EP0517796A1 Oligonucleotide analogs.
12/14/1992	CA2071105A1 Nucleotide sequences
12/10/1992	WO1992021756A1 Methods and compositions relating to genetically engineered cells that produce insulin in response to glucose
12/10/1992	WO1992021750A1 Eukaryotic expression vectors with regulation of rna processing
12/10/1992	WO1992021353A1 Compositions and delivery systems for transdermal administration of neutral oligomers
12/10/1992	WO1992012996A3 Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
12/10/1992	CA2110040A1 Compositions and delivery systems for transdermal administration of neutral oligomers
12/10/1992	CA2109579A1 Eukaryotic expression vectors with regulation of rna processing
12/10/1992	CA2103365A1 Methods and compositions relating to genetically engineered cells that produce insulin in response to glucose
12/09/1992	EP0516664A1 Transgenic animals, cells and cell lines therefrom, and their use
12/04/1992	WO1992021979A1 Methods and compositions relating to genetically engineered cells that produce insulin in response to glucose
12/04/1992	CA2103142A1 Methods and compositions relating to genetically engineered cells that produce insulin in response to glucose
12/01/1992	US5168053 Ribonuclease and genetically-engineered external guide sequence of nucleotides as treatment for AIDS
12/01/1992	CA1310924C Infective drug delivery system
11/1992
11/26/1992	WO1992020823A1 Backbone modified oligonucleotide analogs
11/26/1992	WO1992020822A1 Backbone modified oligonucleotide analogues
11/26/1992	WO1992020703A1 The use of nucleic acid analogues in diagnostics and analytical procedures
11/26/1992	WO1992020702A1 Peptide nucleic acids
11/26/1992	WO1992020356A1 Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
11/26/1992	WO1992020316A2 Targeted delivery of genes encoding immunogenic proteins
11/26/1992	CA2109805A1 The use of nucleic acid analogues in diagnostics and analytical procedures
11/26/1992	CA2103378A1 Backbone modified oligonucleotide analogues
11/26/1992	CA2103064A1 Targeted delivery of genes encoding immunogenic proteins
11/24/1992	US5166195 Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
11/24/1992	US5166059 Genetic engineering to correct gene defects
11/22/1992	CA2103464A1 Backbone modified oligonucleotide analogs
11/19/1992	EP0477290A4 Methods, compositions and devices for growing cells
11/17/1992	WO1992020372A1 Method of suppressing tumor formation in vivo by administering je/mlp-1
11/17/1992	CA2109315A1 Method of suppressing tumor formation in vivo by administering je/mlp-1
11/16/1992	WO1992020808A1 Genomic modifications with homologous dna targeting
11/16/1992	CA2092695A1 Genomic modifications with homologous dna targeting
11/12/1992	WO1992019749A1 Targeted delivery of genes encoding cell surface receptors
11/12/1992	WO1992019281A2 New conjugates, consisting of a glycoprotein and a nucleic acid-binding substance
11/12/1992	WO1992019252A1 Antisense oligonucleotides to c-kit proto-oncogene and uses thereof
11/12/1992	WO1992019195A1 Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
11/12/1992	DE4115038A1 Neue konjugate, bestehend aus einem glykoprotein und einer nukleinsaeure-bindenden substanz New conjugate consisting of a glycoprotein and a nucleic acid-binding substance
11/12/1992	CA2107915A1 Antisense oligonucleotides to c-kit proto-oncogene and uses thereof
11/11/1992	WO1992020697A1 3'-end blocked oligonucleotides
11/11/1992	CA2102804A1 3'-end blocked oligonucleotides
11/09/1992	CA2105771A1 New conjugates, consisting of a glycoprotein and a nucleic acid-binding substance
11/04/1992	EP0511285A1 Vector with multiple target response elements affecting gene expression
11/04/1992	EP0498843A4 Oligonucleotide analogs with novel linkages
10/1992
10/29/1992	WO1992018152A1 Use of müllerian inhibiting substance for treatment of certain tumors
10/29/1992	CA2108264A1 Use of mullerian inhibiting substance for treatment of certain tumors
10/28/1992	EP0510186A1 Therapeutic uses of melanin
10/26/1992	WO1992019732A1 Closed sense and antisense oligonucleotides and uses thereof
10/26/1992	CA2102229A1 Closed sense and antisense oligonucleotides and uses thereof
10/21/1992	EP0457856A4 Isolation growth and differentiation of human muscle cells
10/15/1992	WO1992017505A1 Monoclonal antibodies to stem cell factor receptors
10/15/1992	WO1992017484A1 Single-stranded circular oligonucleotides
10/15/1992	WO1992017211A1 Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences
10/15/1992	WO1992017210A1 Novel protein polycation conjugates
10/15/1992	WO1992017206A1 Wound healing
10/15/1992	WO1992017198A1 Dna and amino acid sequence specific for natural killer cells
10/15/1992	WO1992007939A3 Polypeptide with 46kd hmfg differentiation antigen binding specificity
10/15/1992	CA2107789A1 Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences
10/15/1992	CA2105864A1 Single-stranded, circular oligonucleotides
10/13/1992	US5155218 Dna encoding human 5-ht1d receptors
10/13/1992	US5154921 Removing cells from animal, contacting with polypeptide growth factor, GRO
10/07/1992	EP0506830A1 Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
10/06/1992	US5152757 System for diagnosis and treatment of wounds
10/01/1992	DE4110410A1 New conjugates of poly:cation and protein
10/01/1992	DE4110409A1 Neue protein-polykation-konjugate New protein-polycation conjugates
09/1992
09/23/1992	EP0504327A1 Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof
09/17/1992	WO1992015694A1 Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
09/17/1992	WO1992015693A1 Chimeric tar enzyme construction for hiv therapy
09/17/1992	WO1992015680A1 Methods and compositions for the selective inhibition of gene expression
09/17/1992	WO1992015322A1 Redirection of cellular immunity by receptor chimeras
09/17/1992	CA2108144A1 Methods and compositions for the selective inhibition of gene expression
09/15/1992	WO1991013989A1 Methods and compositions for the treatment of malignancies in which a protein kinase is associated
09/15/1992	CA2078010A1 Methods and compositions for the treatment of malignancies in which a protein kinase is associated
09/02/1992	EP0500799A1 Particle mediated transformation of animal skin tissue cells
08/1992
08/26/1992	EP0483219A4 Enhancement of musculature in animals
08/20/1992	WO1992014829A1 Viral particles having altered host range
08/20/1992	WO1992013950A2 NUCLEOTIDIC SEQUENCES CODING FOR VARIABLE REGIONS OF β CHAINS OF HUMAN T LYMPHOCYTE RECEPTORS, CORRESPONDING PEPTIDIC SEGMENTS AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
08/19/1992	EP0498843A1 Oligonucleotide analogs with novel linkages.

1 ... 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870